Importance of using current NCCLS breakpoints to interpret cefotaxime and ceftriaxone MICs for Streptococcus pneumoniae [3]

Journal of Antimicrobial Chemotherapy

Volumn 51, Issue 2, 2003, Pages 467-468

  Karlowsky, James A ^a   Jones, Mark E ^b  

^a Focus Technologies Incorporated   (United States)

^b Focus Technologies   (Netherlands)

Author keywords

Breakpoints; Cefotaxime; Ceftriaxone; NCCLS; Pneumococci

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFOTAXIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; PENICILLIN G;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL MENINGITIS; BACTERIUM ISOLATE; CEREBROSPINAL FLUID EXAMINATION; HUMAN; LETTER; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STREPTOCOCCUS PNEUMONIAE;

CEFOTAXIME; CEFTRIAXONE; CEPHALOSPORINS; HUMANS; MICROBIAL SENSITIVITY TESTS; PNEUMOCOCCAL INFECTIONS; REFERENCE STANDARDS; STREPTOCOCCUS PNEUMONIAE;

EID: 0037326703     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg108     Document Type: Letter

References (7)

1. Caniça, M., Dias, R., Louro, D., Carvalho, C. & the Multicentre Study Group. (2002). In vitro activity of extended-spectrum cephalosporins against Streptococcus pneumoniae strains with reduced susceptibility to penicillin isolated from patients in Portugal between 1995 and 2000. Journal of Antimicrobial Chemotherapy 50, 611-2.
2. Sahm, D. F., Thornsberry, C., Mayfield, D. C., Jones, M. E. & Karlowsky, J. A. (2002). In vitro activities of broad-spectrum cephalosporins against non-meningeal isolates of Streptococcus pneumoniae: MIC interpretation using NCCLS M100-S12 recommendations. Journal of Clinical Microbiology 40, 669-74.
3. Thornsberry, C., Sahm, D. F., Kelly, L. J., Critchley, I. A., Jones, M. E., Evangelista, A. T. et al. (2002). Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST surveillance program, 1999-2000. Clinical Infectious Diseases 34, Suppl. 1, S4-16.
4. National Committee for Clinical Laboratory Standards. (2002). Performance Standards for Antimicrobial Susceptibility Testing: Twelfth Informational Supplement, M100-S12. NCCLS, Wayne, PA, USA.
5. National Committee for Clinical Laboratory Standards. (1997). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically-Fourth Edition: Approved Standard M7-A4. NCCLS, Wayne, PA, USA.
6. National Committee for Clinical Laboratory Standards. (2001). Performance Standards for Antimicrobial Susceptibility Testing: Eleventh Informational Supplement, M100-S11. NCCLS, Wayne, PA, USA.
7. Vaz Pato, M. V., Carvalho, C., Tomasz, A. & the Multicentre Study Group. (1995). Antibiotic susceptibility of Streptococcus pneumoniae isolates in Portugal. A multicenter study between 1989 and 1993. Microbial Drug Resistance 1, 59-69.